AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26941282 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 0
Study 26941282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25127924 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bacillus coagulans GBI-30, 6086 capsule)
Number of subjects: 17
Study 25127924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25127924 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 17
Study 22394457 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued cannabis use
Number of subjects: 124
Study 22394457 — intervention group
Group type: COMPARATOR
Intervention: Control (no cannabis use)
Number of subjects: 124
Study 20542068 — intervention group
Group type: EXPERIMENTAL
Intervention: LKFibre-containing foods
Number of subjects: 38
Study 20542068 — intervention group
Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 38
Study 18684197 — intervention group
Group type: EXPERIMENTAL
Intervention: On PPI
Number of subjects: 30
Study 18684197 — intervention group
Group type: COMPARATOR
Intervention: Off PPI
Number of subjects: 30
Study 16421034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (lanzoprazole, clarithromycin, and amoxicillin) for 8 days
Number of subjects: 182
Study 16421034 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii plus inulin (SbI) daily for 8 weeks
Number of subjects: 182
Study 16421034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus LB (LB) daily for 8 weeks
Number of subjects: 182
Study 16421034 — intervention group
Group type: COMPARATOR
Intervention: Untreated children (spontaneous clearance)
Number of subjects: 182
Study 14519710 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-3 (four 10-mg capsules per day for the first 4 days, then 8 capsules per day in 2 daily doses for the following 3 days)
Number of subjects: 21
Study 14519710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 21
Study 14519710 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-3
Number of subjects: 21
Study 14519710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14519710 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-3 and Placebo
Number of subjects: 21
Study 10792337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine oestrogen (CEE)
Number of subjects: 124
Study 10792337 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg conjugated equine oestrogen (CEE)
Number of subjects: 124
Study 10792337 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg and 0.3 mg conjugated equine oestrogen (CEE)
Number of subjects: 124
Study 8785958 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine adsorbed to aluminium hydroxide
Number of subjects: 313
Study 8785958 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine adsorbed to calcium phosphate
Number of subjects: 313
Study 8785958 — intervention group
Group type: COMPARATOR
Intervention: Reduced potency assay
Number of subjects: 313
Study 30595443 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 66
Study 30595443 — intervention group
Group type: COMPARATOR
Intervention: Usual-care waiting-list control group
Number of subjects: 66
Study 29753099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea Exertion Scale (DES)
Number of subjects: 188
Study 29753099 — intervention group
Group type: COMPARATOR
Intervention: modified Medical Research Council (mMRC)
Number of subjects: 188
Study 26967157 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide treated curtains (ITCs) distributed to 593 households as part of a cluster-randomized trial.
Number of subjects: 1333
Study 26967157 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who were housewives, knew three or more correct symptoms of dengue, knew at least one correct treatment for dengue, knew someone who had dengue, had children sleeping under a mosquito net, or perceived a change in mosquito amounts.
Number of subjects: 1333
Study 26967157 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who perceived a change in the amount of mosquitoes in the home.
Number of subjects: 1333
Study 24147647 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 20
Study 24147647 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 20
Study 22352435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-Wolfberry (13.7 grams/day)
Number of subjects: 150
Study 22352435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22352435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-Wolfberry
Number of subjects: 150
Study 18988089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream 0.025%
Number of subjects: 64
Study 18988089 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone cream 0.1%
Number of subjects: 64
Study 16859791 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dopaminergic treatment in PD patients
Number of subjects: 0
Study 16859791 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of dopaminergic medication in PD patients
Number of subjects: 0
Study 16859791 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants with hyperechogenicity of the substantia nigra
Number of subjects: 0
Study 16859791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine and tyrosine depletion (APTD) in healthy adults
Number of subjects: 0
Study 16859791 — intervention group
Group type: COMPARATOR
Intervention: Control participants (healthy participants with low echogenicity)
Number of subjects: 0
Study 12599085 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg MEDI‐491
Number of subjects: 24
Study 12599085 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg MEDI‐491
Number of subjects: 24
Study 10910853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 100 microg fentanyl IV (Group 2)
Number of subjects: 66
Study 10910853 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with normal saline IV (Group 1)
Number of subjects: 66
Study 10910853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 100 microg fentanyl IV (Group 3)
Number of subjects: 66
Study 9361930 — intervention group
Group type: COMPARATOR
Intervention: CsA monitoring with T0 (trough levels)
Number of subjects: 20
Study 9361930 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monitoring with T6 (levels obtained 6 h after the morning dose)
Number of subjects: 20
Study 9361930 — intervention group
Group type: COMPARATOR
Intervention: CsA monitoring with T0
Number of subjects: 20
Study 9361930 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monitoring with T6
Number of subjects: 20
Study 1388616 — intervention group
Group type: EXPERIMENTAL
Intervention: Guide-wire technique
Number of subjects: 159
Study 1388616 — intervention group
Group type: COMPARATOR
Intervention: De novo puncture
Number of subjects: 159
Study 3887850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 10
Study 3887850 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 10
Study 30089442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who mentioned cardiovascular conditions
Number of subjects: 361
Study 30089442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who mentioned metabolic conditions
Number of subjects: 361
Study 30089442 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who named < 3 diseases
Number of subjects: 361
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet psycho-emotional needs
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet coping needs
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet care/support needs
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet information needs related to cancer/treatment
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet information needs related to the health care system
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet information needs related to surveillance
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Help dealing with 'worry'
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Help dealing with anxiety
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Help needing to move on with life
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Help dealing with uncertainty about the future
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 1189
Study 26897613 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health status
Number of subjects: 1189
Study 24886552 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol intake (highest quintile)
Number of subjects: 7447
Study 24886552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilbenes
Number of subjects: 7447
Study 24886552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignans
Number of subjects: 7447
Study 24886552 — intervention group
Group type: COMPARATOR
Intervention: Flavonoids
Number of subjects: 7447
Study 24886552 — intervention group
Group type: COMPARATOR
Intervention: Phenolic acids
Number of subjects: 7447
Study 23177487 — intervention group
Group type: EXPERIMENTAL
Intervention: Original clopidogrel bisulphate (600 mg loading dose)
Number of subjects: 60
Study 23177487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrochloride (600 mg loading dose)
Number of subjects: 60
Study 23177487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (600 mg loading dose)
Number of subjects: 60
Study 23177487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (given for 10 days after clopidogrel treatments)
Number of subjects: 60
Study 23177487 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulphate
Number of subjects: 60
Study 23177487 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel besylate
Number of subjects: 60
Study 23177487 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel hydrochloride
Number of subjects: 60
Study 23177487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 60
Study 19523613 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of IM P-in-oil daily for 11 days (group 2)
Number of subjects: 101
Study 19523613 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of IM P-in-oil daily for 6 weeks (group 1)
Number of subjects: 101
Study 18325421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile speed cameras introduced at 29 camera sites
Number of subjects: 29
Study 18325421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile speed cameras at camera sites
Number of subjects: 29
Study 18325421 — intervention group
Group type: COMPARATOR
Intervention: Comparison of crash data before and after camera introduction
Number of subjects: 29
Study 16855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg once daily, Indomethacin 50 mg twice daily
Number of subjects: 0
Study 16855070 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg, Naproxen 500 mg twice daily
Number of subjects: 0
Study 16855070 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 16855070 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 12805333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (ASCT)
Number of subjects: 163
Study 12805333 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 163
Study 10817852 — intervention group
Group type: EXPERIMENTAL
Intervention: Behcet's disease patients
Number of subjects: 71
Study 10817852 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 10817852 — intervention group
Group type: EXPERIMENTAL
Intervention: Behcet's disease patients with diastolic dysfunction
Number of subjects: 71
Study 8640052 — intervention group
Group type: EXPERIMENTAL
Intervention: Information programme on measures to prevent passive smoking, including prolonged communication at one well-child visit and three brochures.
Number of subjects: 443
Study 8640052 — intervention group
Group type: COMPARATOR
Intervention: Control group received no information on smoking.
Number of subjects: 443
Study 1842119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with eicosapentaenoic acid
Number of subjects: 8
Study 1842119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6359877 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and dipyridamole treatment
Number of subjects: 18
Study 6359877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 6359877 — intervention group
Group type: COMPARATOR
Intervention: Paired crossover analysis
Number of subjects: 18
Study 31578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-selected music
Number of subjects: 145
Study 31578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 145
Study 31578781 — intervention group
Group type: COMPARATOR
Intervention: Silent control condition
Number of subjects: 145
Study 31578781 — intervention group
Group type: COMPARATOR
Intervention: Active control (listening to a radio show)
Number of subjects: 145
Study 29747292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy (RRT) in the ELAIN trial (KDIGO stage 2 of AKI)
Number of subjects: 0
Study 29747292 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of renal replacement therapy (RRT) in the ELAIN trial
Number of subjects: 0
Study 29747292 — intervention group
Group type: COMPARATOR
Intervention: Early and late groups of AKIKI trial
Number of subjects: 0
Study 26449391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose i.v. fosaprepitant 150 mg
Number of subjects: 0
Study 26449391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25050672 — intervention group
Group type: EXPERIMENTAL
Intervention: Two burr holes without a drain (Group I)
Number of subjects: 140
Study 25050672 — intervention group
Group type: COMPARATOR
Intervention: Single burr hole with a subdural drain (Group II)
Number of subjects: 140
Study 22951160 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative mitomycin C (MMC) instillation (40 mg MMC in 40 mL saline administered within 6 hours of surgery) followed by delayed BCG instillations (once a week for 6 weeks, 5 x 10^8 colony-forming units in 50 mL saline)
Number of subjects: 51
Study 22951160 — intervention group
Group type: COMPARATOR
Intervention: Delayed BCG instillations alone
Number of subjects: 51
Study 20860912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg twice daily
Number of subjects: 62
Study 20860912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg twice daily
Number of subjects: 62
Study 20860912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily
Number of subjects: 62
Study 20860912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18406674 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal mesh repair (n=19)
Number of subjects: 40
Study 18406674 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair (n=21)
Number of subjects: 40
Study 15973955 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (Cerasorb)
Number of subjects: 10
Study 15973955 — intervention group
Group type: COMPARATOR
Intervention: Autogenous chin bone
Number of subjects: 10
Study 12882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections)
Number of subjects: 39
Study 12882841 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (3.5-10.5 mg daily)
Number of subjects: 39
Study 12882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections) and Glibenclamide (3.5-10.5 mg daily)
Number of subjects: 39
Study 10811082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG capsulotomy
Number of subjects: 6
Study 8641491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of supernumerary follicles
Number of subjects: 227
Study 8641491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of FSH (75 units daily)
Number of subjects: 227
Study 8641491 — intervention group
Group type: COMPARATOR
Intervention: High dosage of FSH (150 units daily)
Number of subjects: 227
Study 8641491 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall multiple pregnancies
Number of subjects: 227
Study 1729043 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection pulse oximeter
Number of subjects: 19
Study 1729043 — intervention group
Group type: COMPARATOR
Intervention: Transmission pulse oximeter
Number of subjects: 19
Study 4089097 — intervention group
Group type: EXPERIMENTAL
Intervention: Center field stimuli
Number of subjects: 0
Study 4089097 — intervention group
Group type: COMPARATOR
Intervention: Peripheral field stimuli
Number of subjects: 0
Study 4089097 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral stimuli
Number of subjects: 0
Study 4089097 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral stimuli
Number of subjects: 0
Study 31310319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically higher serum parathyroid hormone (S-PTH) concentrations
Number of subjects: 184305
Study 30959067 — intervention group
Group type: COMPARATOR
Intervention: Sympathetic ophthalmia (SO)
Number of subjects: 631
Study 30959067 — intervention group
Group type: COMPARATOR
Intervention: Vogt–Koyanagi–Harada (VKH) disease
Number of subjects: 631
Study 28359614 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for Balance Improvement Program (ExBP)
Number of subjects: 61
Study 28359614 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 61
Study 28359614 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi (TC)
Number of subjects: 61
Study 25886150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored return to work intervention program (includes vocational rehabilitation and supportive psychosocial components, therapeutic placement at work)
Number of subjects: 164
Study 25886150 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by the Dutch Social Security Agency
Number of subjects: 164
Study 25886150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored return to work intervention program
Number of subjects: 164
Study 22739328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sand training surface
Number of subjects: 10
Study 22739328 — intervention group
Group type: COMPARATOR
Intervention: Grass training surface
Number of subjects: 10
Study 22052142 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage (15 minutes, 3 times a week, for 3 months)
Number of subjects: 36
Study 22052142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 19194150 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII (30 U/kg)
Number of subjects: 22
Study 19194150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16341543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed sequence stimulation of three digits of both hands
Number of subjects: 0
Study 16341543 — intervention group
Group type: COMPARATOR
Intervention: Random sequence stimulation of three digits of both hands
Number of subjects: 0
Study 15515753 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET
Number of subjects: 28
Study 15515753 — intervention group
Group type: COMPARATOR
Intervention: 67Ga SPECT
Number of subjects: 28
Study 11494096 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of cycle ergometry at 70% VO(2Peak)
Number of subjects: 8
Study 11494096 — intervention group
Group type: COMPARATOR
Intervention: 30 min of quiet seated rest
Number of subjects: 8
Study 9255751 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol (0.05 mg/day once a week)
Number of subjects: 29
Study 9255751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norethisterone acetate (NETA) 1 mg
Number of subjects: 29
Study 9255751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8509588 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 0
Study 8509588 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 8509588 — intervention group
Group type: COMPARATOR
Intervention: Very-low-fat diet rich in lean beef
Number of subjects: 0
Study 2893446 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1 mg
Number of subjects: 8
Study 2893446 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 4 mg
Number of subjects: 8
Study 2893446 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 2 mg
Number of subjects: 8
Study 2893446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29405174 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 78
Study 27387351 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine for 15 days
Number of subjects: 106
Study 27387351 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 106
Study 27387351 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 106
Study 27387351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24462568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Phone group
Number of subjects: 365
Study 24462568 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Coaching group
Number of subjects: 365
Study 24462568 — intervention group
Group type: COMPARATOR
Intervention: Usual care, advice-only control condition
Number of subjects: 365